HF
ARTL icon

HRT Financial’s Artelo Biosciences ARTL Stock Holding History

HRT Financial’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,682
Closed -$44K – 2293
2023
Q3 		$44K Buy
+1,682
New +$56.1K ﹤0.01% 2012
2022
Q2 		– Sell
-104
Closed -$12K – 2900
2022
Q1 		$12K Buy
+104
New +$11.9K ﹤0.01% 2883

Other funds holding ARTL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $1.91B AUM 24.37% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

HRT Financial's ARTL Position: Q4 2023 in Review

HRT Financial sold out of Artelo Biosciences (ARTL) in Q4 2023, closing a stake of 1,682 shares — an estimated $44K sold.

HRT Financial first reported a position in ARTL in Q1 2022 and held it in 2 quarters. The position peaked at $44K in Q3 2023. 4 funds tracked by Wall St. Rank hold ARTL as of Q4 2023.

  • HRT Financial reported no remaining Artelo Biosciences position as of Q4 2023 after selling out during the quarter.
  • HRT Financial sold 1,682 Artelo Biosciences shares in Q4 2023, an estimated $44K.
  • HRT Financial first reported a position in Artelo Biosciences in Q1 2022 and held it in 2 quarters.
  • HRT Financial's Artelo Biosciences position peaked at $44K in Q3 2023.
  • 4 funds tracked by Wall St. Rank held Artelo Biosciences as of Q4 2023.

Based on HRT Financial's 13F filing for Q4 2023, filed 9 Feb 2024.